ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Raze Raises Start-up Funds

by Ann M. Thayer
October 20, 2014 | APPEARED IN VOLUME 92, ISSUE 42

Raze Therapeutics has been launched to pursue a new class of oncology drugs that target mitochondrial one-carbon metabolism. The Cambridge, Mass.-based company’s scientific platform brings together discoveries from its founders Vamsi Mootha at Massachusetts General Hospital, Joshua D. Rabinowitz of Princeton University, and David Sabatini from the Whitehead Institute. The start-up has raised an initial $24 million from venture capital firms and the investment arms of Astellas Pharma, Merck KGaA, and Novartis. Raze will use the money to develop agents that interfere with key anabolic metabolism pathways involved in the growth, biomass accumulation, and survival of tumors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment